Resurgent and Gating Pore Currents Induced by De Novo SCN2A Epilepsy Mutations

被引:31
作者
Mason, Emily R. [1 ]
Wu, Fenfen [2 ]
Patel, Reesha R. [3 ,6 ]
Xiao, Yucheng [4 ]
Cannon, Stephen C. [2 ]
Cummins, Theodore R. [5 ]
机构
[1] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA
[2] Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Indiana Univ Sch Med, Program Med Neurosci, Indianapolis, IN 46202 USA
[4] Indiana Univ Purdue Univ, Sch Sci, Dept Biol, Indianapolis, IN 46202 USA
[5] Indiana Univ Purdue Univ, Sch Sci, Biol Dept Chair, Indianapolis, IN 46202 USA
[6] Scripps Res Inst, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
channelopathies; epilepsy; gating pore current; Nav1.2; resurgent current; whole-cell electrophysiology; SODIUM-CHANNEL ACTIVITY; DE-NOVO MUTATIONS; VOLTAGE SENSOR; FUNCTIONAL-PROPERTIES; PURKINJE NEURONS; ION PERMEATION; GENE SCN2A; C-TERMINUS; INACTIVATION; CANNABIDIOL;
D O I
10.1523/ENEURO.0141-19.2019
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Over 150 mutations in the SCN2A gene, which encodes the neuronal Nav1.2 protein, have been implicated in human epilepsy cases. Of these, R1882Q and R853Q are two of the most commonly reported mutations. This study utilized voltage-clamp electrophysiology to characterize the biophysical effects of the R1882Q and R853Q mutations on the hNav1.2 channel, including their effects on resurgent current and gating pore current, which are not typically investigated in the study of Nav1.2 channel mutations. HEK cells transiently transfected with DNA encoding either wild-type (WT) or mutant hNav1.2 revealed that the R1882Q mutation induced a gain-of-function phenotype, including slowed fast inactivation, depolarization of the voltage dependence of inactivation, and increased persistent current. In this model system, the R853Q mutation primarily produced loss-of-function effects, including reduced transient current amplitude and density, hyperpolarization of the voltage dependence of inactivation, and decreased persistent current. The presence of a Nav/34 peptide (KKLITFILKKTREK-OH) in the pipette solution induced resurgent currents, which were increased by the R1882Q mutation and decreased by the R853Q mutation. Further study of the R853Q mutation in Xenopus oocytes indicated a reduced surface expression and revealed a robust gating pore current at negative membrane potentials, a function absent in the WT channel. This not only shows that different epileptogenic point mutations in hNav1.2 have distinct biophysical effects on the channel, but also illustrates that individual mutations can have complex consequences that are difficult to identify using conventional analyses. Distinct mutations may, therefore, require tailored pharmacotherapies in order to eliminate seizures.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Gating defects of disease-causing de novo mutations in Cav1.3 Ca2+ channels
    Pinggera, Alexandra
    Negro, Giulia
    Tuluc, Petronel
    Brown, Morris J.
    Lieb, Andreas
    Striessnig, Jorg
    CHANNELS, 2018, 12 (01) : 388 - 402
  • [42] Genetic polymorphisms in SCN2A are not associated with epilepsy risk and AEDs response: evidence from a meta-analysis
    Yang, Ruiqing
    Qian, Ruiyi
    Chen, Kerun
    Yi, Wei
    Sima, Xiutian
    NEUROLOGICAL SCIENCES, 2021, 42 (07) : 2705 - 2711
  • [43] Mutations in the Voltage Sensors of Domains I and II of NaV1.5 that are Associated with Arrhythmias and Dilated Cardiomyopathy Generate Gating Pore Currents
    Moreau, Adrien
    Gosselin-Badaroudine, Pascal
    Boutjdir, Mohamed
    Chahine, Mohamed
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [44] Mosaicism of de novo pathogenic SCN1A variants in epilepsy is a frequent phenomenon that correlates with variable phenotypes
    de Lange, Iris M.
    Koudijs, Marco J.
    van 't Slot, Ruben
    Gunning, Boudewijn
    Sonsma, Anja C. M.
    van Gemert, Lisette J. J. M.
    Mulder, Flip
    Carbo, Ellen C.
    van Kempen, Marjan J. A.
    Verbeek, Nienke E.
    Nijman, Isaac J.
    Ernst, Robert F.
    Savelberg, Sanne M. C.
    Knoers, Nine V. A. M.
    Brilstra, Eva H.
    Koeleman, Bobby P. C.
    EPILEPSIA, 2018, 59 (03) : 690 - 703
  • [45] Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model
    Li, Melody
    Jancovski, Nikola
    Jafar-Nejad, Paymaan
    Burbano, Lisseth E.
    Rollo, Ben
    Richards, Kay
    Drew, Lisa
    Sedo, Alicia
    Heighway, Jacqueline
    Pachernegg, Svenja
    Soriano, Armand
    Jia, Linghan
    Blackburn, Todd
    Roberts, Blaine
    Nemiroff, Alex
    Dalby, Kelley
    Maljevic, Snezana
    Reid, Christopher A.
    Rigo, Frank
    Petrou, Steven
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (23)
  • [46] Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression
    Kwan, Patrick
    Poon, Wai Sang
    Ng, Ho-Keung
    Kang, David E.
    Wong, Virginia
    Ng, Ping Wing
    Lui, Colin H. T.
    Sin, Ngai Chuen
    Wong, Ka S.
    Baum, Larry
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (11) : 989 - 998
  • [47] De novo SCN3A missense variant associated with self-limiting generalized epilepsy with fever sensitivity
    Johannesen, Katrine M.
    Gardella, Elena
    Ahring, Philip K.
    Moller, Rikke S.
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2022, 65 (10)
  • [48] Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese
    Li, Xi
    Zhang, Jun
    Wu, Xi
    Yan, Han
    Zhang, Yin
    He, Ruo-Hui
    Tang, Yong-Jun
    He, Yi-Jing
    Tan, Dan
    Mao, Xiao-Yuan
    Yin, Ji-Ye
    Liu, Zhao-Qian
    Zhou, Hong-Hao
    Liu, Jie
    PHARMACOGENOMICS, 2016, 17 (18) : 2007 - 2014
  • [49] Microduplication of SCN2A Gene in a Child with Drug-Resistant Epilepsy and Developmental/Epileptic Encephalopathy with Spike Wave Activation During Sleep
    Akaboshi, Shun
    Okanishi, Tohru
    Iwasaki, Masaki
    Saito, Takashi
    Maegaki, Yoshihiro
    YONAGO ACTA MEDICA, 2024, 67 (03) : 242 - 245
  • [50] De novo EEF1A2 mutations in patients with characteristic facial features, intellectual disability, autistic behaviors and epilepsy
    Nakajima, J.
    Okamoto, N.
    Tohyama, J.
    Kato, M.
    Arai, H.
    Funahashi, O.
    Tsurusaki, Y.
    Nakashima, M.
    Kawashima, H.
    Saitsu, H.
    Matsumoto, N.
    Miyake, N.
    CLINICAL GENETICS, 2015, 87 (04) : 356 - 361